Urinary System Carcinoma — Trials

Urinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 672
Recruiting: 354
Ph III recruiting: 41
Growth YoY: +14%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (391)

clinicaltrialsPublishedShowing 201–250 of 804 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06161532	Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...	recruiting	Phase 2	60	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials
NCT07763197	Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)(SCORE-NMIBC)	recruiting	—	400	Natera, Inc.